Trial Profile
Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI, PEP02, MM-398, Onivyde®) With 5-FU and Leucovorin in Squamous Cell Carcinoma (SCC) of Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
- Indications Head and neck cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Apr 2023 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 25 Mar 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.